Modus Therapeutics Holding Ab · OMXSTO:MODTX
Modus Therapeutics Holding Ab — Fact Sheet (June 2021)
8 slides from Modus Therapeutics Holding Ab's fact sheet, Jun 29, 2021
Slide 1: Invitation to Subscribe for Units in Modus Therapeutics Holding AB
INVITATION TO SUBSCRIBE FOR UNITS IN MODUS THERAPEUTICS HOLDING AB PRIOR TO PLANNED LISTING ON NASDAQ FIRST NORTH GROWTH MARKET Subscription period 29 June - 13 July 2021 IMPORTANT INFORMATION Any investment in securities is associated with risk. The prospectus for Modus Therapeutics Holding AB (‘Mo
Slide 2: Modus in Brief
MODUS IN BRIEF Modus’ patented Unique product based on over 20 years of research – Modus is developing the drug candidate sevuparin to treat sepsis and septic shock. Over 20 years of research have gone into sevuparin’s positive mechanisms polysaccharide has the of action. By harnessing the possibili
Slide 3: Modus
MODUS Modus is a Stockholm-based biotech company the condition is not treated, acute organ failure and severe tissue given the high mortality level and the huge costs involved in sepsis founded in 2011 and part of the corporate portfolio damage may result. Septic shock is one of the leading causes o
Slide 4: Offer in Summary
OFFER IN SUMMARY Subscription period: ISIN code for the share: HOW PROCEEDS FROM THE ISSUE WILL BE USED 29 June - 13 July 2021 SE0015987904. The Company intends to use the funds raised from the initial Offer price: Lock up: issue, totalling approximately SEK 30 million net after issue costs, SEK 6.4
Slide 5: A Paradigm Shift in Sepsis Care - CEO John Öhd
A PARADIGM SHIFT IN SEPSIS CARE CEO JOHN ÖHD The linchpin of our business is the drug candidate Sepsis and septic shock account for the most deaths worldwide The last six months have seen some major changes at Modus. sevuparin and its unique properties. With and there is no drug specifically treatin
Slide 6: Business Model
BUSINESS MODEL Since sevuparin has the potential to be the only drug to specifically treat sepsis and septic shock while greatly reducing healthcare costs, the Modus Board and leadership team expect market interest in sevuparin to be significant in the event of favourable clinical trials. Modus’ bus
Slide 7: Goals
GOALS Modus’ goals span several operational, financial and Modus’ goals extend until 2025, marking the end of the organisational objectives as outlined below. Proceeds from planned phase IIb trials. Once these are complete, it is the the issue for the planned listing will cover the Company’s Company
Slide 8: Goals (continued)
• Last patient treated in Company’s phase Ila Proof-of-Concept trial for sepsis/septic shock. • Presentation of Company at investor meeting, JP Morgan, SF, USA, ahead of the publication of • Phase IIa Proof-of-Concept trial for sepsis/septic shock analysed and top line data data from phase IIb dose